Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.
Overview
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.